What Cifarma does

Cifarma Científica Farmacêutica LTDA is a privately held, family-controlled Brazilian pharmaceutical manufacturer founded in 1999 by Marinho Braga and headquartered in Goiânia, Goiás. The company operates three manufacturing units — a flagship 100,000 m² industrial park in Goiânia producing liquids, semi-solids, sterile liquids, dermocosmetics, and hormonal/sterile products; a Santa Luzia (Minas Gerais) plant producing solid oral dosage forms including effervescent and penicillin lines; and a third unit in Nazário (Goiás). The portfolio spans more than 100 SKUs across three commercial lines (Farma for prescription and generics, MIP/Consumo for OTC, and Mabra) covering generic drugs, over-the-counter medications, vitamin and mineral supplements, phytotherapeutics, and dermocosmetics, with registered brands including Flora 5, Probentol, Claricure, Queimalive, Poslov, Acivirax, and Adecol D3.

Manufacturing operations are ANVISA-certified under RDC 17/2010 BPF/GMP standards, supported by in-house Pharmaceutical Equivalence, microbiological, physical-chemical, analytical development, and packaging materials laboratories. Products are sold exclusively through Brazilian retail pharmacies and drugstores — never direct-to-consumer via marketplaces — distributed via a national logistics operator network and a field sales force of medical representatives covering 24 states. Customer engagement combines traditional trade promotion (Abradilan Conexão Farma, Drogal Collaborator Fair), medical symposiums for healthcare professionals, and content marketing through three company blogs. Cifarma ranks among Brazil's top 20 pharmaceutical groups (19th in IMS Health 2017, up from 23rd in 2016; 20th in ANVISA 2018), though revenue is not publicly disclosed and the business has been entirely self-funded by the founding Braga family without institutional capital.

Name

Cifarma

Legal name

Cifarma Científica Farmacêutica LTDA

Website

https://cifarma.com.br

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Cifarma is a family-owned Brazilian pharmaceutical manufacturer producing 100+ generic, OTC, supplement, phytotherapeutic, and dermocosmetic products across three plants in Goiânia and Minas Gerais, selling exclusively through retail pharmacies and drugstores across 24 states.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industries

Multivitamins & Daily Packs (CRADAGAC), Probiotics & Digestive Health Supplements (CRADAGAF), Herbal & Botanical Supplements (CRADAGAD)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Over-the-counter medications
• Vitamin supplements
• Dermocosmetic products

Headquarters

HQ city

Goiânia

HQ country

Brazil

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products Sales: Sale of generic medications, MIP (medicamentos isentos de prescrição - over-the-counter), prescription medications, supplements, and phytotherapeutics through pharmacies and drugstores across Brazil.
2. Dermocosmetics Sales: Sale of dermocosmetic products for personal care, manufactured at the Goiânia facility.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Cifarma manufactures and distributes a diversified portfolio of more than 100 pharmaceutical products across three commercial lines: Farma (prescription and generic medications), MIP/Consumo (over-the-counter medications, supplements and dermocosmetics), and Mabra. The portfolio covers generic drugs, OTC medications, vitamin and mineral supplements, phytotherapeutics, contraceptives, hormonal products, probiotics, and dermatological products. All products are manufactured at the company's BPF/GMP-compliant facilities in Goiânia (Goiás) and Santa Luzia (Minas Gerais) and sold exclusively through pharmacies, drugstores, and pharmaceutical distributors in Brazil.

Product overview

Cifarma is a 100% Brazilian pharmaceutical company offering a diversified portfolio of products across three commercial lines: Farma (prescription and generic medications), MIP/Consumo (OTC/over-the-counter medications), and Mabra. The portfolio includes over 100 products spanning generic drugs, OTC medications, vitamin and mineral supplements, herbal/fitoterápico products, and dermocosmetics. Key product categories include gastrointestinal probiotics (Flora 5, Flora B, Floralon), vitamin D supplements (Adecol D3), emergency contraceptives (Poslov), dermatological products (Probentol, Queimalive, Claricure), and various generic medications. Products are distributed exclusively through pharmacies and drugstores throughout Brazil.

Differentiator

Problem solved

Functional benefit

Products and services

• Cifarma Generics Portfolio Generic medications manufactured by Cifarma with the same dosage and active ingredient as reference drugs, including Adecol D3, Acenac (acetylcysteine), Acivirax (aciclovir), Acnee Loss (benzoyl peroxide), hormonal generics (algesterone acetophenide + estradiol enanthate, cyproterone acetate + ethinylestradiol), and seven additional generics launched in August 2024. Sold through Brazilian pharmacies and drugstores under the prescription (tarjado) and generic lines.
• Cifarma MIP/OTC Portfolio Over-the-counter (MIP — medicamentos isentos de prescrição) medications and consumer health products sold through Brazilian pharmacies and drugstores without prescription. Includes Nointox (activated vegetable charcoal), Aftine (bismuth/neomycin/procaine oral preparation), Aliviol arnica products, Poslov (levonorgestrel emergency contraceptive, relaunched in 2020 as single-dose tablet), and other OTC items.
• Adecol D3 (Vitamin D3 Supplement) Vitamin D3 supplement in 1000IU drops formulation that promotes immunity and bone/muscle health. Versatile dosing from attack to maintenance dose. Sold in Brazilian pharmacies and drugstores under the Cifarma vitamin supplement line.
• Vitergyl Energy

Quantifiable outcome

• Ranked 19th among pharmaceutical groups in Brazil by IMS Health in 2017
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Universidade Federal de Goiás (UFG)coreStrategic or Co-development PartnerPartnership for scientific research including clinical studies. Flora 5 probiotic study conducted with UFG researchers. Vice-president Sônia Braga visited UFG Faculty of Medicine to learn about medical education technologies. Joint hosting of scientific events for medical residents.
• Universidade de Brasília (UNB)coreStrategic or Co-development PartnerPartnership for scientific research including clinical studies. Flora 5 probiotic study conducted with UFG and UNB researchers.
• Profª Drª Maraci RodriguesminorOthersMedical expert who conducted symposiums on gastrointestinal health with probiotics for Cifarma, sponsored by Flora 5, Floralon, and Flora B products.
• HEMU (Hospital Estadual e Maternidade de Aparecida)coreStrategic or Co-development PartnerPartnership for scientific events. Cifarma hosted scientific meeting in partnership with HEMU focusing on congenital infections during gestational period, bringing together medical residents in gynecology, neonatology, and pediatrics.
• Polícia Militar de GoiásminorOthersCifarma hosted the 25th Intelligence Course graduation ceremony, contributing to community and institutional relationships.
• Instituto AlokcoreGTM or Marketing PartnerPartnership for humanitarian donations. Cifarma donated 40,000 units of medications for SOS RS disaster relief, with Instituto Alok responsible for transporting the cargo via Brazilian Air Force (FAB).
• Grupo Mulheres do BrasilcoreGTM or Marketing PartnerCifarma participated in the 'Unidos Pela Vacina' initiative led by this group, donating materials for COVID-19 vaccination efforts in Goiás municipalities.
• Força Aérea Brasileira (FAB)minorOthersBrazilian Air Force provided transport for humanitarian donations (SOS RS relief) via Instituto Alok partnership.
• SANEAGOminorOthersWater and sanitation company that presented a project on water preservation and sustainability during Cifarma's QSM (Quality, Safety, Environment) Week.
• Hemorrede Pública de GoiásminorOthersBlood network organization that conducted bone marrow donation campaign at Cifarma facilities for the REDOME registry.
• CRF-GO (Conselho Regional de Farmácia do Estado de Goiás)coreStrategic or Co-development PartnerPartnership on self-care practice initiative. CRF-GO collaborated on educational content about over-the-counter medications and pharmacist role in self-care.
• DrogalcoreChannel Partner/ Reseller/ DistributorMajor pharmacy chain in interior São Paulo. Cifarma participated in Drogal's traditional Collaborator Fair 2025, promoting portfolio to chain employees.
• FIEG (Federação das Indústrias do Estado de Goiás)minorOthersPartner in environmental awards (Prêmio Goiás de Gestão Ambiental) and industrial initiatives.
• SEMARH (Secretaria de Meio Ambiente e Recursos Hídricos de Goiás)minorOthersPartner in environmental awards and sustainability initiatives in Goiás.

Scale indicators7 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Eurofarma: Major Brazilian-owned pharmaceutical company with generics, branded specialty, OTC, and hospital lines; comparable in product breadth, multi-state manufacturing footprint, and physician-detailing go-to-market.
• Medley (Sanofi): Brazil's leading pure-play generic drug manufacturer (now part of Sanofi) with national retail pharmacy distribution; directly comparable generic portfolio and channel model to Cifarma.
• Germed Pharma: Brazilian generics-focused pharmaceutical company (part of the Hypermarcas/Grupo Hypera ecosystem) selling through retail pharmacies; comparable pure-generic strategy and pharmacy channel dependence.
• EMS: Brazil's largest pharmaceutical company and a leading generics manufacturer with broad retail and OTC coverage; the closest direct comparable in product mix, channel approach (pharmacy chains), and Brazilian market positioning to Cifarma.
• Biolab Farmacêutica: Brazilian pharmaceutical company focused on prescription, generics, and dermocosmetics sold through pharmacies and medical reps; comparable product mix and go-to-market motion.
• Cristália: Brazilian pharmaceutical manufacturer strong in sterile injectables, hormones, and hospital generics; comparable manufacturing complexity including sterile and hormonal lines, and similar ANVISA GMP operations.
• Apsen Farmacêutica: Brazilian pharmaceutical manufacturer with branded prescription and OTC lines plus supplements; comparable mid-tier positioning and pharmacy-channel distribution model.
• União Química: Brazilian generics and hospital pharmaceuticals manufacturer with diversified dosage forms; directly comparable in generics-heavy portfolio and domestic-only distribution through pharmacies and institutional buyers.
• Aché Laboratórios: Top-tier Brazilian pharmaceutical company operating across prescription, OTC, and dermocosmetics with strong medical promotion; comparable to Cifarma's mix of generics, OTC, and dermatological products under proprietary brands.
• Cimed: Brazilian generic and OTC manufacturer of similar scale competing in retail pharmacies; highly comparable business model centered on affordable mass-market medications and supplements distributed via drugstore chains.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cifarmabrasil

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cifarma